New FDA Approval Brings Hope for Alzheimer’s Patients with Innovative Treatment
In a groundbreaking development for Alzheimer’s disease treatment, the U.S. Food and Drug Administration (FDA) has granted full approval to a novel therapeutic approach that promises to slow cognitive decline in patients with early-stage Alzheimer’s. The approval marks a significant milestone in the fight against a disease that affects more than 6.7 million Americans. The…